[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604812":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":21,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"University Hospital, Essen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Amyloidosis",null,"Oberservation of patients with proven cardiac amyloidosis and Florbetaben PET\u002FMRI as part of diagnostic work up",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"David Kersting, MD, PhD","CONTACT","+492017232073","david.kersting@uk-essen.de",{"name":19,"role":15,"phone":16,"phoneExt":10,"email":20},"Lukas Kessler, MD","lukas.kessler@uk-essen.de",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Department of Nuclear medicine, University Hospital Essen","RECRUITING","Essen","North Rhine-Westphalia","45147","Germany","DE",{"type":31,"coordinates":32},"Point",[33,34],7.01228,51.45657,{"lat":34,"lon":33},[37],{"name":14,"role":15,"phone":38,"phoneExt":10,"email":17},"+49 2017232073",{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100604812","hybrid-florbetaben-petmri-for-imaging-of-cardiac-amyloidosis-100604812",false,"NCT07154381","Hybrid Florbetaben PET\u002FMRI for Imaging of Cardiac Amyloidosis","Monocentric Observational Trial for Florbetaben PET\u002FMRI Hybrid Imaging in Patients With Cardiac Amyloidosis","Inclusion Criteria:\n\n* Age \\> 40 years\n* proven Amyloidosis (ATTR or AL)\n* Women: negative pregnancy test less than weeks prior imaging.\n\nExclusion Criteria:\n\n* Patients receiving amyloidosis-specific treatment prior study inclusion.\n* Patients participating in other clinical trails for treatment of Amyloidosis.\n* Pregnancy\n* Contraindiactions for MRI (eGFR\\\u003C30ml\u002Fmin\u002F1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI).\n* inability of consent\n* Refusal of consent","ALL","40 Years",{"count":51,"type":52},25,"ESTIMATED","36 Months","OBSERVATIONAL","Exploration of prognostic parameters in 18F-Florbetaben PET\u002FMRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).",[57],"Cardiac Amyloidosis",[59,60],"PET\u002FMRI","Florbetaben","2025-08-26",{"date":63,"type":64},"2025-09-04","ACTUAL",{"date":66,"type":64},"2019-12-09",{"date":68,"type":52},"2025-12",{"name":5,"class":6},1]